PD-1 and PD-L1 in Single-Target and Multi-Target Combination Therapies for Non-Small Cell Lung Cancer (NSCLC)

Juncheng Shao

doi:10.54097/br887039

Authors

Juncheng Shao

DOI:

https://doi.org/10.54097/br887039

Keywords:

PD-1, PD-L1, non-small cell lung cancer (NSCLC), Immune checkpoints targeted therapy.

Abstract

Lung cancer ranks as the most prevalent malignant tumor, exhibiting a higher annual incidence rate compared to other cancers. In clinical practice, treatment approaches currently encompass traditional chemotherapy alongside newer strategies such as immune checkpoint inhibitors, notably PD-1 and PD-L1 inhibitors, to manage patient care. While conventional chemotherapy has been widely adopted in clinical settings as a standard method to combat tumors, its effectiveness in treating non-small cell lung cancer (NSCLC) remains limited and often falls short of expectations. In contrast, emerging therapies involving PD-1 or PD-L1 inhibitors, either as single-target treatments combined with chemotherapy or as dual-target regimens combining both PD-1 and PD-L1 inhibitors, have been explored in clinical trials and have demonstrated promising outcomes. These innovative approaches appear to offer improved efficacy over traditional methods, sparking interest in their potential to transform NSCLC management. This article provides a comprehensive summary of the current landscape of PD-1 and PD-L1 therapies for NSCLC, drawing on an extensive review of existing literature. By synthesizing findings from recent studies, it aims to shed light on the advancements, challenges, and future directions of these immunotherapeutic strategies in the context of NSCLC treatment, contributing to a deeper understanding of their role in modern oncology.

Downloads

Download data is not yet available.

References

[1] Testa, U., G. Castelli and E. Pelosi, Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel), 2018. 10 (8).

[2] Zhou, F., M. Qiao and C. Zhou, The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol, 2021. 18 (2): p. 279-293.

[3] Liu, B., Y. Song and D. Liu, Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol, 2017. 10 (1): p. 174.

[4] Buchbinder, E.I. and A. Desai, CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol, 2016. 39 (1): p. 98-106.

[5] Hui, E., et al., T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science, 2017. 355 (6332): p. 1428-1433.

[6] Kamphorst, A.O., et al., Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science, 2017. 355 (6332): p. 1423-1427.

[7] Xia, L., Y. Liu and Y. Wang, PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist, 2019. 24 (Suppl 1): p. S31-S41.

[8] Cheng, W., et al., Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol, 2024. 17 (1): p. 54.

[9] Guo, K., et al., Overcoming radiation-induced PD-L1 upregulation by novel gadolinium-palladium nanoplatforms for enhanced tumor radio-immunotherapy. CHEMICAL ENGINEERING JOURNAL, 2025. 504 (158754).

[10] Zhou, Y., et al., Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients with Resectable NSCLC: An Indirect Meta-Analysis. JAMA Netw Open, 2024. 7 (3): p. e241285.

[11] Heymach, J.V., et al., Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med, 2023. 389 (18): p. 1672-1684.

[12] Maggie Liu, S., et al., PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Sci Bull (Beijing), 2024. 69 (4): p. 535-543.

[13] Li, Z., et al., Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. Pharmacol Res, 2020. 160: p. 105194.

[14] Phillips, W., et al., Efficacy of PD-1/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review. Crit Rev Oncol Hematol, 2024. 196: p. 104288.

[15] Yin, J., et al., Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. Front Immunol, 2022. 13: p. 830631.

[16] Ravi, A., et al., Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet, 2023. 55 (5): p. 807-819.

[17] Cui, Y., et al., B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma. J Exp Clin Cancer Res, 2023. 42 (1): p. 146.

[18] Zhang, Q., et al., Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Front Immunol, 2021. 12: p. 663986.

[19] Wang, Y., et al., Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis from Non-Small Cell Lung Cancer. Front Immunol, 2022. 13: p. 829451.

[20] Alifu, M., et al., Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis. Front Oncol, 2023. 13: p. 1146905.